EFNB2 and cancer: The EphB4-ephrinB2 signaling axis is aberrantly expressed in a variety of cancers, highlighting it as a promising therapeutic target (Alam et al., 2008; Broggini et al., 2020; Piffko et al., 2022; Sharma et al., 2015; Xu et al., 2023).